Overview

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical resection and local radiation therapy. Although these patients are relatively rare, there is currently no established standard of treatment for a disease that causes a great deal of morbidity, and that is eventually fatal.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Genentech, Inc.
Novartis
Treatments:
Bevacizumab
Everolimus
Sirolimus